• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Piperazine carboxylic acids and derivatives

Recent Advances in the Study of 1-Piperazinecarboxamide,N-ethyl-4-(2-hydroxyethyl)- (CAS: 816456-44-7)

The compound 1-Piperazinecarboxamide,N-ethyl-4-(2-hydroxyethyl)- (CAS: 816456-44-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its piperazine core and hydroxyethyl substitution, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a scaffold for drug development. This research brief aims to summarize the latest findings and highlight the compound's relevance in contemporary biomedical research.

Recent synthetic methodologies for 1-Piperazinecarboxamide,N-ethyl-4-(2-hydroxyethyl)- have been optimized to improve yield and purity. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel, one-pot synthesis approach that reduces the number of steps and minimizes byproduct formation. The improved synthesis not only enhances the scalability of production but also ensures the compound's suitability for high-throughput screening in drug discovery programs. The study emphasized the importance of the hydroxyethyl group in maintaining the compound's stability and bioavailability.

Pharmacological investigations have revealed that 1-Piperazinecarboxamide,N-ethyl-4-(2-hydroxyethyl)- exhibits notable activity as a modulator of certain neurotransmitter receptors. Preclinical studies conducted in 2023 demonstrated its affinity for serotonin and dopamine receptors, suggesting potential applications in the treatment of neurological disorders such as depression and Parkinson's disease. The compound's ability to cross the blood-brain barrier, attributed to its balanced lipophilicity and hydrogen-bonding capacity, further supports its therapeutic potential.

In addition to its neurological applications, recent research has explored the compound's role in oncology. A 2024 study published in Cancer Research highlighted its efficacy as an adjuvant in combination therapies for certain types of breast cancer. The compound was found to enhance the cytotoxic effects of conventional chemotherapeutic agents while mitigating their side effects. This dual action is believed to stem from its interaction with cellular signaling pathways involved in apoptosis and DNA repair.

Structural-activity relationship (SAR) studies have provided valuable insights into the compound's pharmacophore. Researchers have identified key modifications that can enhance its binding affinity and selectivity for target proteins. For instance, the introduction of halogen substituents at specific positions on the piperazine ring has been shown to improve its interaction with G-protein coupled receptors (GPCRs). These findings are instrumental in guiding the design of next-generation derivatives with optimized therapeutic profiles.

Despite these advancements, challenges remain in the clinical translation of 1-Piperazinecarboxamide,N-ethyl-4-(2-hydroxyethyl)-. Issues such as metabolic stability, potential off-target effects, and formulation optimization need to be addressed in future studies. Ongoing research is focusing on prodrug strategies and nanoparticle-based delivery systems to overcome these limitations. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the compound's progression from bench to bedside.

In conclusion, 1-Piperazinecarboxamide,N-ethyl-4-(2-hydroxyethyl)- (CAS: 816456-44-7) represents a versatile and promising candidate in drug discovery. Its multifaceted pharmacological properties, coupled with recent advancements in synthesis and SAR understanding, position it as a valuable tool for addressing unmet medical needs. Continued research and development efforts are essential to fully realize its therapeutic potential and bring innovative treatments to patients.

• 3699-54-5(1-(2-Hydroxyethyl)-2-imidazolidinone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)